Recently, published studies [35, 36] dealing with biochemically recurrent prostate cancer reported higher tumor detection rates in patients under ADT, suggesting the assumption that the effect of ADT on PSMA expression changes within the course of the disease. Here, FOLH1 is linked to prostate cancer.